Safety & Side Effects
Across its published trials, amycretin's side-effect profile looked like the GLP-1 and amylin class it builds on: gastr…
Mostly the gut, with class questions to watch
Across its published trials, amycretin's side-effect profile looked like the GLP-1 and amylin class it builds on: gastrointestinal events dominated and were dose-dependent. In the oral first-in-human trial every one of the 364 events was mild or moderate; in the subcutaneous early-phase trial the majority were mild to moderate, which is a weaker statement and worth reading precisely. The 2026 phase 2 diabetes papers describe the same pattern. Layered on top are class warnings and a few theoretical amylin-specific concerns.
This unit separates the common-and-manageable from the serious-but-rare from the purely theoretical, and is honest that the long-term safety record for amycretin simply does not exist yet.
Key terms
The gut side effects
The overwhelming majority of amycretin's observed side effects were gastrointestinal: nausea, vomiting, and decreased appetite. In the oral phase 1, all adverse events were mild or moderate and GI events made up about half. In the subcutaneous trial, gastrointestinal events were again the most common treatment-emergent adverse events and the majority were mild to moderate, a weaker statement than "all" and worth reading precisely. They were dose-dependent and worst during dose escalation, exactly the class pattern. The checklist below adds one non-gastrointestinal effect that belongs to the class rather than to amycretin specifically.
The reassuring part is that these effects were manageable and mostly transient, blunted by slow titration. The unreassuring part is that they are dose-dependent, and because amycretin engages two gastric-slowing arms, the GI burden could be prominent at higher doses, exactly where the biggest weight-loss numbers came from.
AdvancedWhy two gastric-slowing arms can add GI burden
Both GLP-1 and amylin slow gastric emptying, so a co-agonist engages that mechanism twice. This is the flip side of the additive-benefit story: the same actions that add weight loss also partly add nausea and fullness. In the small early trials the profile stayed mild to moderate, but whether the higher-dose GI burden is tolerable for most people over the long term is an open question phase 3 must answer.